KITLG and cancer: In fact, evidence shows cancer cells with a misregulated UPS are more sensitive to the broad-spectrum proteasome/SCF-targeting inhibitors than non-cancerous cells, which allows for the use of lower drug concentrations for effective outcomes and reduced side effects (Ludwig et al., 2005).